Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Receivables - Net (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Receivables - Net for 16 consecutive years, with $115.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net fell 4.87% to $115.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $115.3 million, a 4.87% decrease, with the full-year FY2025 number at $115.3 million, down 4.87% from a year prior.
  • Receivables - Net was $115.3 million for Q4 2025 at Myriad Genetics, down from $118.0 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $137.0 million in Q2 2025 to a low of $91.3 million in Q4 2021.
  • A 5-year average of $111.1 million and a median of $114.8 million in 2023 define the central range for Receivables - Net.
  • Biggest YoY gain for Receivables - Net was 39.21% in 2021; the steepest drop was 8.2% in 2021.
  • Myriad Genetics' Receivables - Net stood at $91.3 million in 2021, then rose by 11.28% to $101.6 million in 2022, then increased by 12.5% to $114.3 million in 2023, then increased by 6.04% to $121.2 million in 2024, then fell by 4.87% to $115.3 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Receivables - Net are $115.3 million (Q4 2025), $118.0 million (Q3 2025), and $137.0 million (Q2 2025).